Drug intelligence / Profile preview

CV6-1271

Development stage: Preclinical
Lead developer: CV6 Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

CV6-1271 is a novel, orally bioavailable small molecule inhibitor of dUTPase (deoxyuridine triphosphatase) currently in preclinical development by CV6 Therapeutics. Designed to address unmet needs in inflammatory diseases, CV6-1271 is intended for use in combination with standard-of-care treatments like methotrexate, particularly for the treatment of rheumatoid arthritis. By inhibiting dUTPase, the drug aims to modulate the activity of pathogenic immune cells and enhance the therapeutic index of anti-folate medications, potentially leading to improved symptom control and patient outcomes.

Targets

dUTPase (Deoxyuridine triphosphatase)

Beyond the preview

Go deeper on CV6-1271.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CV6-1271.

Explore the full profile